BiotechTubeBiotechTube
Home/Pipeline/SCD-117

SCD-117

Atopic Dermatitis

Phase 2Completed

Key Facts

Indication
Atopic Dermatitis
Phase
Phase 2
Status
Completed
Company
SPARC

About SPARC

SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.

View full company profile

Therapeutic Areas

OphthalmologyNeurologyDermatologyOncology

Other Atopic Dermatitis Drugs

DrugCompanyPhase
LebrikizumabEli LillyPhase 3
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
KHK4083Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b